Bérengère Gruson

Lenalidomide with or without erythropoietin in transfusion-dependent erythropoiesis-stimulating agent-refractory lower-risk MDS without 5q deletion

Andréa Toma, Olivier Kosmider, Sylvie Chevret et al. · Leukemia · 2015 · 120 citations · Full text

Hematological Malignancy, Transfusion Medicine, Hematology +4

How should we diagnose and treat blastic plasmacytoid dendritic cell neoplasm patients?

Francine Garnache‐Ottou, Chrystelle Vidal, Sabeha Biichlé et al. · Blood Advances · 2019 · 120 citations · Full text

<i>IDH1/2</i>but not<i>DNMT3A</i>mutations are suitable targets for minimal residual disease monitoring in acute myeloid leukemia patients: a study by the Acute Leukemia French Association

Houria Debarri, Delphine Lebon, Christophe Roumier et al. · Oncotarget · 2015 · 97 citations · Full text

First‐line autologous stem cell transplantation in primary CNS lymphoma

Marie Brevet, Réda Garidi, Bérengère Gruson et al. · European Journal Of Haematology · 2005 · 58 citations

Next-generation sequencing of FLT3 internal tandem duplications for minimal residual disease monitoring in acute myeloid leukemia

Jean‐Emmanuel Bibault, Martin Figeac, Nathalie Hélevaut et al. · Oncotarget · 2015 · 53 citations · Full text